Heart Transplantation for Chagas Cardiomyopathy

Maria da Consolação Moreira, Fabio Morato Castilho, Renato Braulio, Guilherme Ferraz Messina de Pádua Andrade, José Renan da Cunha Melo

Universidade Federal de Minas Gerais (UFMG), Minas Gerais, MG – Brazil.

Abstract

Heart transplantation (HT) is an established treatment for patients with advanced heart failure (HF). Chagas disease (CD), caused by the Trypanosoma cruzi (T.cruzi) is an important cause of HF in Latin America. Considering CD is a chronic infectious disease, the use of immunosuppressive therapy after HT can reactivate T. cruzi infection and compromise outcomes. Early diagnosis and treatment of this complication is extremely important, which requires knowledge, experience, and a high degree of suspicion by transplant physicians. Furthermore, with the international immigration of people, CD is no longer exclusive to Latin America, since a large number of immigrants with T. cruzi infection are living in non-endemic countries. This phenomenon represents not only a new global epidemiological problem, but also a challenge for transplant teams. This review aims to discuss the peculiarities of HT in the context of CD, with a focus on reactivation of the infection, clinical manifestations, etiological treatment of T. cruzi and differential diagnosis with allograft rejection, among HT recipients.

Introduction

Heart transplantation (HT) is an established treatment for selected patients, with advanced heart failure (HF), with refractory to optimal medical treatment, and without contraindications that would compromise the outcomes.1,2 The procedure in these patients has proven to be a treatment that is effective in decreasing mortality rates and improving patients’ quality of life.3 At present, not only are the number of heart transplant candidates increasing, but they are also becoming much more complex.3,4 The great advances that have occurred in the field of transplants notwithstanding, there are still challenges to be faced:

• older age of both recipients and donors;
• the need for mechanical circulatory support (not available in several Centers);
• the growing use of combined organ transplants;
• high proportion of sensitized candidates;
• shortage of organ donors;
• uncommon etiologies of HF requiring HT;
• Chagas disease (CD) as a worldwide challenge and the complexity of T. cruzi infection reactivation.5,7

In the past, CD was considered a contraindication for heart transplantation due to the possibility of reactivation of T. cruzi infection as a consequence of immunosuppressive therapy to prevent allograft rejection.3,8 The first heart transplant due to CD was performed in Brazil in June 1985, by Dr Euryclides de Jesus Zerbini, in the city of São Paulo.8 Since then, CD has emerged as a complex indication for heart transplant, and even today it remains a challenge for transplant teams in endemic countries. As a result, CD has added more challenges to the field of transplantation.

Brazilian physicians were pioneers in performing HT in chagasic patients, gaining experience in this new area of transplants. From 1985 on, HT has become a well-established alternative for patients with end-stage Chagas heart disease.5,9,10 Despite the complexity of the reactivation of T. cruzi infection, which occurs frequently in HT recipients, its proper diagnosis allows for an adequate treatment and ensures a good prognosis.5,6

Keywords

Trypanosoma cruzi; Chagas disease; Cardiomyopathy; Heart failure; Heart transplantation.

Mailing Address: Maria da Consolação Moreira
Av. Alfredo Balena, 190. Postal Code: 30130-110, Belo Horizonte, MG – Brazil.
E-mail: mariacvmoreira@gmail.com

DOI: https://doi.org/10.36660/iwcs.20200248

Manuscript received August 14, 2020; revised manuscript August 14, 2020; accepted August 23, 2020.
Peculiarities of Chagas Disease in the Context of Heart Transplant

Since 1990, several intergovernmental initiatives coordinated by both the Pan American Health Organization (PAHO) and the World Health Organization (WHO) have been implemented in an attempt to eliminate domestic triatomines and to prevent transmission via blood transfusions in Latin America. As a consequence, the number of new cases of infection was significantly reduced. However, an estimated 7,968,094 T. cruzi infected individuals worldwide, mostly in Latin America, have been reported.

The increased flow of individuals from rural areas to large cities and the international migration of people has led to a globalization of the disease that is no longer exclusive to Latin America. A large number of immigrants with chronic T. cruzi infection are living in non-endemic countries, such as those in North America and the European Union, as well as in Australia and Japan. This fact causes concern for transplant teams and a challenging epidemiological problem.

Chagas disease is characterized by an acute phase after an initial infection followed by a chronic form. The acute phase, usually asymptomatic or accompanied by mild symptoms, progresses with high levels of T. cruzi in the blood, proliferation of amastigote forms in various tissues, and resolution in 4 to 8 weeks. The patients then evolve to the chronic form, with low parasitemia levels. The chronic form is also divided into indeterminate, an asymptomatic form that can persist for life, and a clinically symptomatic form occurring in 20% to 30% of all cases. The cardiac, digestive, or cardio-digestive clinical manifestations may appear even decades after the initial infection. The chronic cardiac form includes arrhythmias, conduction defects, HF, and sudden cardiac death. Heart failure due to Chagas etiology has a worse prognosis and a higher mortality rate when compared to other etiologies.

Chagas disease is the third leading cause of HT in endemic countries, corresponding to 35% of all patients undergoing the procedure. The reactivation of chronic infection by T. cruzi may occur in conditions of immunosuppression, such as AIDS, cancer undergoing chemotherapy, or after the use of immunosuppressive drugs, such as in the context of organ transplants.

Transplant professionals from endemic and non-endemic countries need to be aware of the risk of T. cruzi transmission from infected donors to recipients as well as to the risk of reactivation of chronic infection in organ transplant recipients, receiving immunosuppressive therapy to avoid allograft rejection.

Recipient Selection and Listing Criteria

The indications and contraindications for HT in the setting of CD follow the classic HT guideline criteria for other HF etiologies. A patient with severe terminal HF refractory to optimal medical treatment and without formal contraindications, might benefit from the procedure and should be included on the waiting list for a heart transplant. Clinical treatment needs to be optimized for symptom relief and to improve survival, necessarily including the following drugs: an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker, or angiotensin receptor-neprilysin inhibitor added to a beta blocker (in maximum tolerated doses) and a mineralocorticoid antagonist if possible.

Some peculiarities in the selection of HT potential donors and recipients in the context of CD should be observed. Chagas patients usually have lower values of pulmonary arterial pressure, which can reduce right ventricular dysfunction, a frequent complication in the postoperative period of HT. Thus, cardiac manometry by right cardiac catheterization may not be always necessary before HT. Most of these patients come from poor rural areas. Social inequalities may influence results and survival rates after HT, but these issues are still not well understood. However, it seems that the patient’s socioeconomic condition has no impact on outcomes after HT. The megaesophagus and megacolon may occur in CD as a cardio-digestive form and should be evaluated. Depending on the severity of digestive manifestation, these may constitute contraindications to the procedure.

Chagas cardiomyopathy is a highly arrhythmogenic disease, and sudden cardiac death corresponds to 55%-65% of all deaths, frequently caused by malignant arrhythmias, such as tachycardia and ventricular fibrillation. Patients with malignant ventricular arrhythmias usually receive an implantable cardioverter-defibrillator (ICD). They may require multiple ICD therapies, more than 4 shocks per day, featuring an electrical storm. This group of patients might also benefit from a heart transplant.

In Brazil, according to governmental regulation, serology for T. cruzi infection in all potential donors and recipients is mandatory, and a positive donor for heart
recipients is not accepted. Potential organ donors and recipients should always be screened for Chagas disease, in both endemic and non-endemic countries whose potential donor/recipient has a positive epidemiology.

Mechanical circulatory support has a potential benefit as a bridge for HT in chagasic patients. However, due to the high costs, this device is not available in the Public Health System (SUS in Portuguese) in Brazil, which funds more than 90% of heart transplants in the country.

Immunosuppression Strategies

Induction therapy for HT, regardless of the etiology of HF, consists of intense immunosuppressive therapy during the transplant procedures or in its immediate postoperative period. It is recommended in high-risk patients in an attempt to reduce the risk of hyperacute rejection or delay the use of higher doses of calcineurin inhibitors, thus minimizing kidney damage. The most widely used inducing agents are polyclonal anti-thymocyte immunoglobulins (polyclonal antibody - thymoglobulin) and interleukin 2 receptor inhibitors, which have low immunogenicity, such as daclizumab and basiliximab.

Basic immunosuppressive therapy for the maintenance of heart transplant patients generally includes a calcineurin inhibitor agent (Cyclosporin A or tacrolimus). These agents must be associated with mycophenolate mofetil, an inhibitor of anergy, rapamycin, or everolimus. Prednisone is associated with this standard regimen and, in most patients, can be suspended six months after the transplant, in the absence of rejection.

In the context of Chagas disease, induction and/or maintenance immunosuppressive therapy can reactivate T. cruzi infection.

There are no randomized control clinical studies comparing the various immunosuppressive regimens in HT chagasic patients. However, a greater number of reactivations have been described in recipients using mycophenolate mofetil. Therefore, it is recommended that Chagas patients receive the lightest immunosuppressive therapy, as long as there is no rejection.

Diagnosis and Treatment of Rejection

Graft rejection is an important cause of morbidity and mortality after heart transplant in general, although the incidence of treated rejection continued to decline. In the last decade, only 12.6% of HT recipients were treated for rejection between hospital discharge and one year after transplant.

Rejection is classified into hyperacute, antibody-mediated, and acute cellular rejection (ACR), the last representing the most prevalent form of rejection in an HT setting. Histologically, it is defined by inflammatory infiltrates, which are typically lymphocyte predominant, and associated myocyte injury. The International Society for Heart and Lung Transplantation (ISHLT) has revised (R) categories of ACR as follows: 0R (no rejection), 1R (mild), 2R (moderate), or 3R (severe).

Hyperacute rejection is mediated by preformed antibodies to the allograft in the recipients and manifests as a severe graft failure within minutes or a few hours after the HT procedure. It is now uncommon due to the advent of prospective cross-matching and more potent immunosuppressive therapy.

Antibody-mediated rejection is poorly defined and challenging, especially in HT performed for Chagas cardiomyopathy. The frequency of hyperacute rejection and antibody-mediated rejection after HT due to CD have not been reported.

Although rejection is a major cause of death amongst chagasic recipients, occurring in 10%–14% of all patients, no difference in the incidence of rejection episodes (grade 2R or 3R) between HT recipients with or without Chagas disease has been reported.

To date, there are no laboratory markers for rejection. Most patients are asymptomatic, and symptoms, when present, are vague and nonspecific. Thus, early detection of cardiac rejection relies on histological diagnosis through endomyocardial biopsy (EMB), the gold standard method for the diagnosis, and the monitoring of allograft rejection. Despite its invasiveness, EMB is associated with a very low morbidity and mortality when performed by experienced operators. In most transplant centers, it is used for routine rejection surveillance, varying the frequency of biopsies in Center protocols.

A myocarditis secondary to reactivation of the T. cruzi infection in the transplanted heart can often occur, which makes the differential diagnosis between allograft rejection and reactivation of Chagas' disease a great challenge.

Endomyocardial biopsy is considered the best method for the differential diagnosis between inflammation caused by immunological rejection and T. cruzi infection reactivation. The definition of one of these two conditions is still a challenge if parasites are not found at the biopsy fragments. Under routine histopathology staining techniques, if parasites are not seen, the inflammatory histopathological features found in either rejection (grade 2R or 3R) or reactivation are quite similar. Thus, the detection of an inflammatory mononuclear
infiltrate in the EMB slides is not enough to rule out the diagnosis of Chagas disease reactivation and poses a medical dilemma as the aggressive immunosuppressive treatment to abort rejection may facilitate Chagas disease reactivation.5

The findings of T. cruzi amastigote nests with inflammatory mononuclear infiltrates in the EMB fragments do not exclude concomitant allograft rejection, as the two conditions may occur concomitantly.

The therapy of rejection in transplant recipients with and without Chagas disease is similar. In general, a mild grade of rejection (ISHLT 1R), in the absence of clinical or hemodynamic compromise, generally do not require additional intervention. However, higher grades (≥ 2R) require an aggressive supplemental immunosuppression. The majority of cases with ACR respond properly to pulse corticosteroid therapy, although rescue therapy may be required for certain patients.5,21

Rejection constitutes a risk factor for Chagas reactivation, as over 85% of all patients have at least one rejection episode before reactivation occurs.5

Moreover, up to 43% of all patients with findings of inflammatory infiltrate compatible with the diagnosis of 2R or 3R rejection, at EMB fragments, do not respond to immunosuppressive therapy, but they do show a good response to anti-trypanosomal drug treatment.5

Post Heart Transplant T. Cruzi Infection Reactivation

Clinical presentation

The instituted immunosuppressive therapy increases the risk of T. cruzi infection reactivation. The incidence after HT varies from 19.6% to 90% in Brazil.9,20,24 A recent publication from a United States case series shows a rate of CD reactivation of 61%, which is within the broad range reported here.26

The Latin America Guideline for the Diagnosis and Treatment of Chagas Heart Disease has established several risk factors for reactivation, as follows:25,26

- number of rejection episodes;
- intensity of Immunosuppression;
- use of mycophenolate mofetil;
- presence of malignancy;
- HIV infection and other immunosuppression status.5

Considering the potential morbidity and mortality, the diagnosis and appropriate management of Chagas disease reactivation in the context of organ transplants is extremely important. Therefore, this procedure must be performed within a structured clinical and laboratory protocol to monitor the reactivation of the infection and its subsequent treatment.5,9,13 The diagnosis of reactivation is based on clinical signs and symptoms and/or the presence of parasites in blood, cerebrospinal fluid and other fluids, bone marrow, or tissues.5,9

After HT, the patient must be closely and regularly monitored. Clinical monitoring aims to identify the first signs of reactivation and promptly establish anti-T. cruzi treatment. Clinical reactivation has cardiac and extra-cardiac manifestations, including: myocarditis, ventricular dysfunction, arrhythmias, new atrioventricular/intraventricular blocks on the ECG, new skin lesions (subcutaneous nodules, panniculitis), fever, bone marrow involvement or neurological manifestations. The central nervous system involvement is a rare and severe clinical manifestation. It manifests through meningoencephalitis, chagoma, brain abscess, or stroke, as well as through spacing-occupying lesions in the white matter of the brain.5,27

Figure 1 is an example of post-heart transplant Chagas reactivation.

The myocarditis of the reactivation can be mistakenly diagnosed as a graft rejection, receiving intensified immunosuppressive treatment, which will aggravate the reactivation of the infection.26 The differential diagnosis between rejection and reactivation myocarditis is still a major challenge. In the presence of inflammatory infiltrate, amastigote nests and/or positive PCR for T. cruzi in the myocardium, it can be said that there is a reactivation, but it is impossible to safely exclude associated allograft rejection. Despite this complexity, the survival rates of chagasic patients undergoing HT do not differ from other etiologies.9,20

Parasitological diagnosis of reactivation

The purpose of laboratory monitoring is to identify any subclinical signs of reactivation before cardiac and extra-cardiac symptoms, as well as allograft dysfunction.5,13 Serological tests are useful only in potential donors, in the diagnosis of chagasic cardiomyopathy in potential recipients, and in seronegative recipients who receive organs from seropositive donors.5,13 These tests play no role in the diagnosis of reactivation. Traditionally, laboratory monitoring has used parasitological methods (direct blood search of T. cruzi and blood cultures) and serial histological examinations of EMB, in search of T. cruzi amastigotes, in tests with low sensitivity.5,13 In recent years, several studies have demonstrated the value of the PCR test in peripheral blood and EMB fragments.
in detecting early reactivation, before the appearance of symptoms and/or cardiac allograft dysfunction. Several studies have shown that PCR analysis is able to detect \textit{T.cruzi} either in the blood or in EMB before clinical manifestations of reactivation by two or more months. Currently, PCR diagnosis is a precious tool to help physicians decide whether patients should begin treatment with anti-parasite drugs or changes in the immunosuppression protocol.

It is very important to monitor HT recipients for early detection of \textit{T.cruzi} reactivation, allowing etiological treatment before clinical manifestations appear. However, no specific definition about when and how the monitoring protocol should be applied is available. Some centers agree that Chagas recipients should be routinely monitored for \textit{T.cruzi} reactivation as they are monitored for rejection and any time when clinical suspicion occurs. Variations in the protocol can occur depending on the transplant team’s policy.

Thus, concerning the frequency of clinical visits, laboratory monitoring, and EMB, there is still no consensus in the literature. Table 1 is our suggestion for a clinical, laboratory, and histological monitoring protocol for chagasic patients undergoing HT and the etiological treatment, which is in line with main available guidelines. In countries where Chagas disease is not endemic, failure to identify patients with Chagas disease reactivation constitutes a major medical problem, as severe or fatal outcomes may supervene the incapacity to establish a proper diagnosis.

**Etiological treatment of reactivation**

Benznidazole and nifurtimox are the anti-trypanosomal drugs of choice and have proven to be effective when administered to patients in the acute phase of Chagas disease and in those showing \textit{T.cruzi} infection reactivation. However, their efficacy upon the chronic phase has been a subject of debate.
Thus, etiological treatment for Chagas disease is recommended for patients with acute infection, congenital infection, women of childbearing age for the prevention of vertical transmission, and reactivated infection in immunosuppressed patients. Other chronically infected people in the early chronic phase (especially children less than 15 years of age) may also benefit from treatment. Antiparasitic treatment is not recommended for patients in the chronic phase with advanced cardiomyopathy, as is the case of the heart transplant candidates, since there is no evidence of benefit. There is no evidence to support the prophylactic anti-
T. cruzi treatment strategy for reactivation.

In the heart transplant scenario, the presence of clinical manifestations of T. cruzi infection reactivation or identification of the parasite in the blood, cerebrospinal fluid, EMB fragments, or in other tissues constitute sufficient evidence to begin etiological treatment without delay. Benznidazole, a nitroimidazole derivative, is the first-line treatment drug of choice. Each tablet contains 100mg of the active substance. It is absorbed by the gastrointestinal tract and predominantly excreted by the kidneys, with a half-life of 12 hours. The recommended dose is 5mg/kg/day, for 60 days, with the daily dose being divided into two or three times. Its most important side effect is urticarial dermatitis, which occurs in about 30% to 60% of all patients, commonly occurring early at the end of the first week of treatment, presenting a good therapeutic response with the use of antihistamines or small doses of corticosteroids. In a few cases, fever and adenomegaly may appear, in which case the medication should be discontinued. Other adverse effects include polyneuropathy, with pain and/or tingling in the lower limbs. Anorexia, significant leukopenia, and agranulocytosis are rare, and when present, the interruption of treatment is mandatory.

Nifurtimox is not available in Brazil. These trypanosomicidal medications are contraindicated in pregnant women and in patients with either renal or hepatic impairment. A patient may have more than one reactivation episode after treatment. Therefore, it is necessary to maintain the monitoring of reactivation after anti-T. cruzi treatment.

Post Heart Transplant Complications and Survival

The clinical outcomes, morbidity, and mortality in HT recipients with and without Chagas disease are similar. In both classes of patients, the major complications reported after transplant are almost the same: allograft dysfunction (20%); rejection (2R or 3R, 10%-14%); bleeding (10%); non T. cruzi infection (20%-30%); acute kidney failure

| Table 1 – Clinical and laboratory monitoring of T. cruzi infection reactivation after heart transplantation in Chagas disease and etiological treatment |
|---------------------------------|
| **Procedure** |
| **Before transplantation** |
| - Serological tests for Chagas disease for the donor |
| - Serological tests for Chagas disease for the potential recipient with some possibility of Chagas cardiomyopathy |
| **After transplantation** |
| - Periodic clinic visits with attention to signs/symptoms of reactivation, including ECG and Echocardiogram |
| - Routine blood T. cruzi test (smear, blood culture) for diagnosis of infection reactivation |
| - Routine blood test for T. cruzi by PCR if available |
| - Routine periodic endomyocardial biopsies, with T. cruzi search (histology, immunohistochemistry, and PCR analysis, when available) |
| - Search of T. cruzi in tissues (skin, bone marrow, among others) in a suspicion of T. cruzi infection |
| **Frequency of procedures after transplantation** |
| - First month: weekly |
| - Second month: every two weeks |
| - Third to sixth month: monthly |
| - Seventh to 12th month: every 3 months |
| - After 12 months: every six months |
| **Etiological treatment of reactivation** |
| - Benznidazole 5mg/Kg/day for 60 days |
| Adapted from references 23, and 26. |
(up to 70%); cardiac allograft vasculopathy, which seems to be less frequent in chagasic recipients. Moreover, a reported higher incidence of malignancy has not been confirmed in all series.8-10,20,35

In Brazil, the survival rate of Chagas patients undergoing HT is 76%, 71%, and 46% at six months, 5 and 10 years respectively, which is better when compared to the cohort of patients undergoing HT due to other etiologies.8-10 It has been postulated that the reason for the detected differences may well be due to particular chagasic patient characteristics, such as their young age, less comorbidities, and less previous cardiac surgery.8-10

However, it should be emphasized that the only national registry compiling the results of HT in Brazil was carried out in 1999, more than 20 years ago.6,9,10

Conclusions

Heart transplantation is an established treatment for end-stage Chagas cardiomyopathy. The reactivation of T. cruzi infection occurs frequently in HT recipients, but a proper diagnosis allows for an adequate treatment and ensures a good prognosis. The survival rate of Chagas patients undergoing HT is better when compared to patients undergoing HT due to other etiologies.

Despite many advances in this complex field, there are still many unanswered questions and challenges. Chagas disease (American trypanosomiasis) is no longer exclusive of Latin America. The globalization of Chagas disease also requires attention and knowledge from transplant teams in non-endemic countries. Failure to diagnose Chagas disease in potential organ donors and recipients from endemic areas, as well as reactivation after transplant can evolve to fatal consequences.

With the incorporation of PCR techniques, the reactivation concept should be revised. The differential diagnosis between rejection and reactivation remains a challenge and warrants further study. Multicenter studies comparing different immunosuppression protocols are desirable, as are a national registry to assess candidate selection, the management of immunosuppression to prevent and treat rejection episodes, the treatment of eventual T. cruzi reactivation, patient surveillance, and the evaluation of long-term results from the procedure.

Author Contributions

Conception and design of the research: Moreira MCV. Acquisition of data: Moreira MCV, Andrade GFMP. Analysis and interpretation of the data: Moreira MCV, Castilho FM, Cunha-Melo JR. Writing of the manuscript: Moreira MCV, Castilho FM, Andrade GFMP, Cunha-Melo JR. Critical revision of the manuscript for intellectual content: Moreira MCV, Cunha-Melo JR.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Mehra MR, Canter EC, Hannan MM, Semigran MJ, Uber PA, Baran, DA et. al. The 2016 International Society for Heart Lung Transplant listing criteria for heart transplant: A 10-year update. J Heart Lung Transpl. 2016; 35:1-23.http://dx.doi.org/10.1016/j.healun.2015.10.023.
2. Bacal F, Marcondes-Braga FG, Rohde LEP, Xavier Júnior JL, de Souza Brito F, Moura LZ, et al. 3ª Diretriz Brasileira de Transplante Cardíaco. Arq Bras Cardiol. 2018; 111(2):230-289. DOI:10.5935/abc.20180153.
3. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes Jr D, Hsich E et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplant: Thirty-sixth adult heart transplant report — 2019; focus theme: Donor and recipient size match. J. Heart Lung Transplant. 2019; 38(10): 1056-1066. doi:10.1016/j.healun.2019.08.004.
4. Hunt SA, Haddad F. The Changing Face of Heart Transplant. J. Am.Coll. Cardiol. 2008; 52(8):587-598. doi:10.1016/j.jacc.2008.05.020
5. Andrade JP, Marin-Neto JÁ, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. Arq. Bras. Cardiol. 2011; 97(2 Suppl 3): 1-48. ISSN 0066-782X - https://doi.org/10.1590/S0066-782X20110000100001
6. Kramsford EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplant. Curr. Opin. Infect. Dis. 2014; 27(5): 418–424. PMID: 25023742 DOI: 10.1097/QCO.0000000000000088.
7. Lee BY, Bacon KM, Bottazzi ME, Hotze PJ. Global economic burden of Chagas disease: A computational simulation model. Lancet Infect. Dis. 2013; 13: 342-348, doi:10.1016/S1473-3099(13)70002-1.
8. Hunt SA, Haddad F, The Changing Face of Heart Transplant. J. Am.Coll. Cardiol. 2008; 52(8):587-598. doi:10.1016/j.jacc.2008.05.020
9. Andrade JP, Marin-Neto JÁ, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F et al. Sociedade Brasileira de Cardiologia. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. Arq. Bras. Cardiol. 2011; 97(2 Suppl 3): 1-48. ISSN 0066-782X - https://doi.org/10.1590/S0066-782X20110000100001
10. Kramsford EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplant. Curr. Opin. Infect. Dis. 2014; 27(5): 418–424. PMID: 25023742 DOI: 10.1097/QCO.0000000000000088.
8. Carvalho VB, Sousa EFL, Vila JHA, Silva JP, Caiado MR, Araujo SRR et al. Heart Transplant in Chagas' Disease -10 Years After the Initial Experience. Circulation. 1996;94(8):1815-1817. https://doi.org/10.1161/01.CIR.94.8.1815

9. Bocchi EA, Fiorelli A. First Guidelines Group for Heart Transplant of the Brazilian Society of Cardiology. The paradox of survival results after heart transplant for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg. 2001;71:1183-8. DOI: 10.1016/s0003-4979(01)00258-2

10. Bocchi EA, Fiorelli A. First guideline group for heart transplant of the Brazilian Society of Cardiology: the Brazilian experience with heart transplant: a multicenter report. J Heart Lung Transplant 2001;20:637-645. DOI: 10.1053/jhlt.2001.00239-7

11. Dias JCP. Southern Cone Initiative for the elimination of Triatoma infestans and the interruption of transmission of Chagas disease: historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz. 2007;102(Suppl 1):11-8. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762007000100002&lng=en&tlng=en

12. World Health Organization. Chagas Disease (American Trypanosomiasis) [Internet]. Geneva: World Health Organization 2015, cited 2020, May 29 at http://www.who.int/mediacentre/factsheets/fs340/en/.

13. Dias JCP, Ramos AN Jr, Contijo ED, Luqueti A, Shikanai-Yasuda MA, Coura J et al. 2nd Brazilian Consensus on Chagas Disease, 2015; Rev. Soc. Bras. Med. Trop. 2016; 49(Supplement I): 1-60. doi: 10.1590/0066-782x-2016-2016.333.

14. Freitas HFG, Chizzola PR, Paes AT, Lima ACP, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1,220 outpatients with heart failure: role of Chagas’ heart disease. Int. J. Cardiol. 2005; 102: 239-247 DOI: 10.1016/j.jcc.2004.05.025.

15. Ponikowski P, Anker SD, Bueno H, Chua MY, Ciabattoni G, Cockell S et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-20. doi: 10.1093/eurheartj/hew128

16. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACC/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2013;62(16):1670-200. DOI: 10.1016/j.jacc.2013.08.037

17. Comité Coordenador da Diretirz de Insuficiência Cardiaca. Diretirz Brasileira de Insuficiência Cardiaca Crónica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539. DOI: 10.5935/abc.20180190

18. Parra AV, Rodrigues V, Cancella S, Cordeiro JÁ, Bestetti RB. Impact of socioeconomic status on outcome of a Brazilian heart transplant recipients cohort. Int. J. Cardiol. 2008; 125: 142-143. doi:10.1016/j.ijcard.2007.01.038.

19. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol 2001;76:75-96. DOI: 10.1016/s0003-4979(01)00100008

20. Bestetti RB, Theodoropoulos TAD. A Systematic Review of Studies on Heart Transplant for Patients with End-Stage Chagas’ Heart Disease. J. Cardiac Failure 2009; 15(3): 249-255. DOI: 10.1016/j.card. fail.2008.10.023.

21. Costanzo MR, Dipchand A, Starling R, Anderson AS, Chan M, Desai S et al. The international society of heart and lung transplant guidelines for the care of heart transplant recipients. J. Heart Lung Transplant. 2010; 29: 914-956. DOI: 10.1016/j.healun.2010.05.034.

22. Bacal F, Silva CP, Bocchi EA, Pires PV, Moreira LFP, Issa VS et al. Mycoplasmale autotrophus motile Chagas disease reactivation in heart transplanted patients: Comparison between two different protocols. Am J Transplant. 2005;5(8):2017-21. doi:10.1111/j.1600-6143.2005.00975.x.

23. Stewart S, Winters GL, Fishbein MC, Tzabelaa HA, Kobashigawa J, Abrams J et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710-20. DOI:10.1016/j.healun.2005.03.019.

24. Fiorelli AL, Santos RH, Oliveira JL, Lourenço-Filho DD, Dias RR, Oliveira AS et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant. Proc. 2011; 43(1): 220-224. PMID: 21335192 DOI: 10.1016/j.transproceed.2010.12.046.

25. From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin. Proc. 2011;86: 1095–1102 doi:10.4065/mcp.2011.0296.

26. Gray EB, La Hoz RM, Green JS, Vikram HR, Benedict T, Rivera H et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transpl. Infect. Dis. 2018, 20(6):1-8, e12996. DOI:10.1111/tid.12996.

27. Camargos S, Moreira MCV, Portela DMMC, Lira JPI, Modesto FVS, Menezes GMN et al. CNS chagoma - Reactivation in an immunosuppressed patient. Neurology 2017; 88: 605-606. PMID: 20406601 DOI: 10.1179/1600-6124.2017.6.226033.

28. Souza MM, Franco M, Almeida DR, Diniz RV, Mortara RA et al. Comparative histopathology of endomyocardial biopsies in chagasic and non chagasic heart transplant recipients. J Heart Lung Transplant 2001; 20:534–543. PMID: 11343980 DOI: 10.1016/S1053-2498(00)00320-X.

29. Maldonado C, Albano S, Vettorazzi L, Salomone O, Zlocovciski JCZ, Abega C et al. Using polymerase chain reaction in early diagnosis of non chagasic heart transplant recipients. J Heart Lung Transplant 2004; 23:1345–1348. PMID: 15607662 DOI: 10.1016/j.healun.2003.09.027.

30. Diaz M, Favaloro L, Bertolotti A, Burgos JM, Vigliano C, Lastra MP et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow-up in heart transplant. Am J Transplant. 2007; 7:1633–1640. DOI: 10.1111/j.1600-6143.2007.01820.x

31. Qvarnstrom Y, Schijman AG, Veron V, Aznar C, Steurer F, Silva AJ. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multitarget real-time PCR approach. PLoS Negl Trop Dis 2012; 6:e1689. https://doi.org/10.1371/journal.pntd.0001689

32. Costa PA, Segatto M, Durso DF, Moreira WJ, Queiroz L, Castilho FA et al. PCR screening and treatment of Chagas disease in organ transplant recipients in the United States, 2012-2016. Transpl. Infect. Dis. 2018, 20(6):1-8, e12996. DOI:10.1111/tid.12996.

33. Chinh-PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: Recommendations from the Chagas in transplant working group. Am. J. Transplant. 2011; 11: 672–680, doi:10.1111/j.1600-6143.2011.03444.x.

34. Jackson Y, Dang T, Schmetzer B, Pasqual M, Meylan P. Trypanosoma cruzi fatal reactivation in heart transplant recipient in Switzerland. J. Heart, Lung. Transplant. 2011; 30(4): 484-485. PMID: 20120630 DOI: 10.1011/jtid.12996.

35. Ortega AE, López ZRDA, Pérez RH, Millón CF, Martin AD, Palomo YC et al. Kidney failure after heart transplant. Transplant. Proc. 2010; 42: 3193–3195 DOI:10.1016/j.transproceed.2010.05.049.